Literature DB >> 9039093

Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans.

M J Morris1, H S Cox, G W Lambert, D M Kaye, G L Jennings, I T Meredith, M D Esler.   

Abstract

Neuropeptide Y coexists with norepinephrine in sympathetic nerves and is coreleased into the circulation on sympathetic activation. Little is known about the regional release of neuropeptide Y in humans under normal conditions or in pathophysiological situations of sympathetic activation or denervation. We measured plasma neuropeptide Y-like immunoreactivity and norepinephrine concentrations in samples taken from the brachial artery; coronary sinus; and internal jugular, antecubital, or hepatic veins in volunteers aged 20 to 64 years. Regional neuropeptide Y overflow at rest was calculated from venoarterial plasma concentration differences and plasma flow, and norepinephrine spillover was determined by [3H]norepinephrine infusion techniques. Cardiac release of neuropeptide Y and norepinephrine was examined in response to various stressors as well as in clinical models of sympathetic activation, cardiac failure, and denervation after cardiac transplantation. In healthy volunteers, cardiac, forearm, and jugular venous sample neuropeptide Y concentrations were similar to arterial levels. Hepatic vein plasma neuropeptide Y was greater than arterial both at rest (119 +/- 5% of arterial, n = 7) and after a meal (132 +/- 12%, n = 7), with neuropeptide Y overflows of 6 +/- 2 and 11 +/- 2 pmol/min, respectively. In contrast, hepatomesenteric norepinephrine spillover was not significantly increased by feeding. Although coronary sinus plasma norepinephrine concentrations increased significantly with the cardiac sympathetic activation accompanying mental arithmetic, coffee drinking, isotonic exercise, and bicycle exercise, only the latter powerful sympathetic stimulus increased neuropeptide Y overflow. Cardiac failure was associated with increased resting release of both norepinephrine and neuropeptide Y from the heart, whereas postcardiac transplant norepinephrine spillover from the heart was reduced. The net overflow of neuropeptide Y to plasma observed at rest across the hepatic circulation, but not the cardiac, forearm, or cerebral circulations, indicates that the gut, the liver, or both make a major contribution to systemic plasma neuropeptide Y levels in humans. Sympathetic activation by exercise produced a modest increase in cardiac neuropeptide Y overflow but to only approximately 25% of the resting input from the gut and without a change in arterial neuropeptide Y concentration. Plasma neuropeptide Y measurements are less sensitive than those of plasma norepinephrine concentrations as an index for quantifying sympathetic neural responses regulating the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039093     DOI: 10.1161/01.hyp.29.1.137

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

1.  Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation.

Authors:  Oliver Dörr; Sebastian Ewen; Christoph Liebetrau; Helge Möllmann; Luise Gaede; Dominik Linz; Mathias Hohl; Christian Troidl; Timm Bauer; Michael Böhm; Christian Hamm; Felix Mahfoud; Holger Nef
Journal:  Clin Res Cardiol       Date:  2015-05-26       Impact factor: 5.460

Review 2.  Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome.

Authors:  Elisabeth A Lambert; Gavin W Lambert
Journal:  Curr Hypertens Rep       Date:  2011-06       Impact factor: 5.369

3.  Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses.

Authors:  Kuixing Zhang; Fangwen Rao; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Brian Vaught; Yuhong Chen; Tiffany A Greenwood; Andrew J Schork; Lei Wang; Manjula Mahata; Mats Stridsberg; Srikrishna Khandrika; Nilima Biswas; Maple M Fung; Jill Waalen; Rita P Middelberg; Andrew C Heath; Grant W Montgomery; Nicholas G Martin; John B Whitfield; Dewleen G Baker; Nicholas J Schork; Caroline M Nievergelt; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2012-09-26       Impact factor: 24.094

4.  Motilin- and neuropeptide Y-like immunoreactivity in a psychophysiological stress experiment on patients with functional dyspepsia.

Authors:  B H Jonsson; P M Hellström
Journal:  Integr Physiol Behav Sci       Date:  2000 Oct-Dec

Review 5.  Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics.

Authors:  M Esler; D Kaye
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 6.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

7.  Stronger correlation with myocardial ischemia of high-sensitivity troponin T than other biomarkers.

Authors:  Theodore Pipikos; Alkistis Kapelouzou; Diamantis I Tsilimigras; Yannis Fostinis; Marina Pipikou; Athanassios Theodorakos; Antonis N Pavlidis; Christos Kontogiannis; Dennis V Cokkinos; Maria Koutelou
Journal:  J Nucl Cardiol       Date:  2018-01-29       Impact factor: 5.952

Review 8.  Sympathetic activation in congestive heart failure: an updated overview.

Authors:  Guido Grassi; Fosca Quarti-Trevano; Murray D Esler
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

Review 9.  Adrenergic signaling in heart failure: a balance of toxic and protective effects.

Authors:  Anthony J Baker
Journal:  Pflugers Arch       Date:  2014-03-14       Impact factor: 3.657

10.  Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis.

Authors:  Svati H Shah; Neil J Freedman; Lisheng Zhang; David R Crosslin; David H Stone; Carol Haynes; Jessica Johnson; Sarah Nelson; Liyong Wang; Jessica J Connelly; Michael Muehlbauer; Geoffrey S Ginsburg; David C Crossman; Christopher J H Jones; Jeffery Vance; Michael H Sketch; Christopher B Granger; Christopher B Newgard; Simon G Gregory; Pascal J Goldschmidt-Clermont; William E Kraus; Elizabeth R Hauser
Journal:  PLoS Genet       Date:  2009-01-02       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.